Article in Pediatric blood & cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 7 institutions in 1 country.
Kris Ann P SchultzCancer and Blood Disorders, Children's Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-1788-5832
Murali ChintagumpalaDivision of Hematology-Oncology, Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
Jin PiaoUniversity of Southern California Keck School of Medicine, Los Angeles, California, USA.
Kenneth S ChenDepartment of Pediatrics, UT Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0003-2304-4631
Robyn GartrellDivision of Pediatric Hematology/Oncology, Department of Pediatrics, Columbia University Irving Medical Center, New York, New York, USA.ORCID 0000-0003-3287-4223
Emily Christison-LagayDivision of Pediatric Surgery, Yale School of Medicine, Yale New-Haven Children's Hospital, New Haven, Connecticut, USA.
Jesse L BerryThe Vision Center, Children's Hospital Los Angeles, The Saban Research Institute, Children's Hospital Los Angeles, USC Roski Eye Institute, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.ORCID 0000-0002-8907-9100
Rachana ShahDivision of Hematology-Oncology, Department of Pediatrics, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.ORCID 0000-0002-8445-2172
Theodore W LaetschDivision of Oncology, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-8497-3138
Children's Oncology Group Rare Tumor CommitteeCancer and Blood Disorders, Children's Minnesota, Minneapolis, Minnesota, USA.
University of Southern California · USBaylor College of Medicine · USCenter for Cancer and Blood Disorders · USChildren's Hospital of Philadelphia · USColumbia University Irving Medical Center · USSouthwestern Medical Center · USYale New Haven Hospital · US
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
COG U24 Funding 2026-2027U24CA196173 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Mignon Lee-Cheun Loh, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$62.5M
Detecting DICER1: A global partnership to cure pediatric lung cancerR37CA244940 · NCI · CHILDREN'S HOSPITALS AND CLINICS · PI Kris Ann Pinekenstein Schultz · 2020 to 2026
$2.4M
Development of a surrogate liquid biopsy from the aqueous humor in retinoblastoma eyes.K08CA232344 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI BERRY, JESSE L · 2018 to 2022
The Children's Oncology Group (COG) Rare Tumor Committee includes the Infrequent Tumor and Retinoblastoma subcommittees, encompassing a wide range of extracranial solid tumors that do not fall within another COG disease committee. Current therapeutic trial development focuses on nasopharyngeal carcinoma, adrenocortical carcinoma, pleuropulmonary blastoma, colorectal carcinoma, melanoma, and thyroid carcinoma. Given the rarity of these tumors, novel strategies and international collaborative efforts are necessary to advance research and improve outcomes.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Children's Oncology Group's 2023 blueprint for research: Rare tumors. · full record | OpenQuestion